CClinicalTrials.gg
CompletedNCT05211752e-VOG(YA)Updated May 18, 2022

Eye Movements Recording Using a Mobile : Comparison to Standard Video-oculography in Young Athletes

An observational study in Healthy, sponsored by Association de Recherche Bibliographique pour les Neurosciences. Completed at 1 site in Monaco. Open to participants aged 15 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-18.

Sponsored by Association de Recherche Bibliographique pour les Neurosciences · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
46
Ages
15 Years to 20 Years
Sex
All
01

Study summary

This study aims to compare measurements obtained through the e-VOG application (mobile application, usable on smartphones or tablets, to measure eye movements) with measurements from the standard video-oculography device (Eye-Tracker®T2), in young athletes.

Read the detailed description

e-VOG Young athletes is a collaborative study between the Memory Center of the Rainier III Center (Princess Grace Hospital, Monaco), the Neurology Department of Nice University Hospital (France), and the AS Monaco Football Academy medical team.

Memory Center of the Rainier III Center is expert in eye-tracking and is equipped with a standard video-oculography device (Eye-Tracker®T2), which records eye movements at a high frequency and measures saccades parameters (latency, speed, amplitudes etc...).

e-VOG is a mobile application, home-developed by the Neurology Department team of Nice University Hospital, to measure eye movements.

Based on literature, investigators hypothesize that video-oculography could integrate assessment protocols for head trauma occurring during sports practice. The nomadic nature of the e-VOG application would make possible to assess oculomotor behaviors to a subject who has just suffered a trauma and who is suspected of having a concussion.

From this perspective, it seems necessary to firstly validate baseline values of the e-VOG application in a population of athletes without major health problems, and who have not presented concussion.

02

Conditions studied

  • Healthy

Keywords

  • Young Athletes
03

Who can participate

Ages eligible
15 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Young athletes for whom a standard video-oculography exam is prescribed by the AS Monaco Football medical team as part of a preventive and follow-up approach performed in routine care.

Eye-tracking is a relevant and essential assessment for the detection and monitoring of neuro-cognitive alterations in young athletes which may result from macro-trauma (concussion) or repeated micro-trauma (head game) occurring during the season.

Standard video-oculography exam is carried out at the Center Rainier III (Princess Grace Hospital), in accordance with usual practices. It is a non-invasive device for eye movements recording, allowing doctors to measure standard parameters related to eye movements (Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE).

Inclusion criteria

  • Young Athletes from AS Monaco Football Academy
  • referred by AS Monaco Medical Team to perform a video-oculography (Eye-Tracking) examination as part of routine care.
  • covered by a health insurance system
  • volunteer, able to give free, informed and written consent.
  • For minors: whose holder of parental authority has given their written consent to participate following the information given by investigator.

Exclusion criteria

Exclusion Criteria:

  • General anaesthesia within 3 months.
  • Head trauma within 3 months
  • Neurological, ophthalmological or general pathology preventing the realization of a video-oculography examination.
  • Oculomotor abnormality detectable on clinical examination by the neurologist prescribing the standard video-oculography examination.
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
46 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthy young athletes (Eye-Tracker®T2 + e-VOG)

    Subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.

    Other: eVOG (Mobile VideoOculoGraphy)

  • Healthy young athletes (e-VOG + Eye-Tracker®T2)

    Subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.

    Other: eVOG (Mobile VideoOculoGraphy)

Interventions

  • OthereVOG (Mobile VideoOculoGraphy)

    * Eyes movements assessed with e-VOG (mobile application, that uses the face detection features of the front camera to detect and record eye movements). * Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)

05

What researchers measure

Primary outcomes

  1. Oculomotor profiles concordance

    Analyze of the concordance of the profiles obtained between the e-VOG digital assessment and the standard video-oculography assessment. Evaluation criteria: For each assessment, patients will be classified according to the number of oculomotor abnormality observed (based on identified parameters assessments: latency / speed / gain / altered ocular pursuits / fixation disorders / presence of internuclear ophthalmoplegia), in accordance with the literature standards.

    Time frame: Day 0

Secondary outcomes

  1. Latency during horizontal reflex saccades

    Measure of Latency during an horizontal reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device. Evaluation criteria: latency (reaction time in ms).

    Time frame: Day 0

  2. Latency during vertical reflex saccades

    Measure of Latency during a vertical reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device. Evaluation criteria: latency (reaction time in ms).

    Time frame: Day 0

  3. Latency during horizontal voluntary saccades

    Measure of Latency during an horizontal volontary saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device. Evaluation criteria: latency (reaction time in ms).

    Time frame: Day 0

  4. Velocity during horizontal reflex saccades

    Measure of Velocity during an horizontal reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device. Evaluation criteria: velocity (mean and peak velocity) in °/s.

    Time frame: Day 0

  5. Velocity during vertical reflex saccades

    Measure of Velocity during a vertical reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device. Evaluation criteria: velocity (mean and peak velocity) in °/s.

    Time frame: Day 0

  6. Inhibition capacity

    Measure of inhibition capacity performance during an antisaccades" paradigm with e-VOG Compared to the one evaluated with standard video-oculography device. Evaluation criteria: percentage of errors.

    Time frame: Day 0

  7. Internuclear ophthalmoplegia (INO) detection

    Highlight presence/absence of INO with e-VOG Compared to standard video-oculography device. Evaluation criteria: INO is present if calculated ratio of abducting to adducting eye movement (both mean and peak velocity) is \>1.

    Time frame: Day 0

  8. Fixations impairments detection

    Highlight presence/absence of Fixations impairments with e-VOG Compared to standard video-oculography device. Evaluation criteria: presence/absence/frequency of square wave-jerks, nystagmus, flutters.

    Time frame: Day 0

  9. Impairment of horizontal smooth pursuit

    Highlight Impairment of horizontal smooth pursuit with e-VOG Compared to standard video-oculography device. Evaluation criteria: presence/absence of saccade and perturbation.

    Time frame: Day 0

  10. Impairment of vertical smooth pursuit

    Highlight Impairment of horizontal smooth pursuit with e-VOG Compared to standard video-oculography device. Evaluation criteria: presence/absence of saccade and perturbation.

    Time frame: Day 0

06

Study locations

1 site
  • Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital
    Monaco, 98000, Monaco
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05211752
Lead sponsor
Association de Recherche Bibliographique pour les Neurosciences
Collaborators
Centre Hospitalier Princesse Grace, Centre Hospitalier Universitaire de Nice, Association Sportive Monaco Football Club
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Jan 18, 2022
Primary completion
Feb 22, 2022
Completion
Feb 22, 2022
Last update
May 18, 2022

Study contacts

Mikael COHEN, MD
principal investigator · Centre de Ressources et de Compétences SEP, UMRC Pasteur 2, Université Nice Côte d'Azur, Nice-France
Sandrine LOUCHART de la CHAPELLE, MD-PHD
principal investigator · Centre Mémoire, Centre de Gérontologie Clinique RAINIER III, Princess Grace Hospital, Monaco
Alain PESCE, PUPH
study director · Association de Recherche Bibliographique pour les Neurosciences
Sylvain BLANCHARD, MD-PHD
principal investigator · Association Sportive Monaco Football Club

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion